CD8A and cancer: In vivo T cell priming assays showed that SRA silencing conferred DCs increased functionality in stimulating adoptively transferred ICD-reactive CD8+ T cells (Figure 1D), suggesting that targeted inhibition of SRA may be used to increase the immunotherapeutic potency of chaperone-based cancer vaccines.